Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The new CEO is expected to join the BoD "early October" , and so next week in my book....let's hope he has plenty to report and fingers crossed his remit as CEO is more than just the development of SFX-01 across multiple disease targets...Evgen is all set for some serious growth imho and on a one way trajectory from small cap to mid cap player....with the very real chance of a M & A strategic investor / commercial JV partner in the pipeline....$$$$....Gla ;-)
"completed tens of M&A transactions and managed many drug development programmes"
When the news will filter out to the market, we should see huge focus on Evgen ...imo
Only just a waiting game from now on ...
Well done viable, I'm sure any educated guess will become clearer when the new CEO provides an update on proceedings. Gl :-)
Courtesy of Bumpa on Adfvn...:-)
More on the new CEO...
”
Dr Huw Jones
Non-Executive Director
Huw is Executive Chairman of Chronos Therapeutics in Oxford UK and strategic advisor to Gen 2 neuroscience in Cambridge UK. During his time at Chronos he extracted the company from Oxford University, raised substantial grant and equity finance and led Chronos’ acquisition of three early research programmes in brain disease from Shire PLC. He was surprised and pleased to have been awarded European CEO of the year 2016/17 for drug discovery by European CEO Magazine, alongside leaders in their sectors from Adidas, Unilever and Spotify. Huw advises Gen 2 Neuroscience in Cambridge, UK. Gen2 has a unique technology targeting dementias and tauopathies and is funded by the UK Dementia Discovery fund.
Previous posts include: NED, then rescue CEO, Ardana PLC; non–executive chairman, Ashbourne Pharmaceuticals; president Europe, CV Therapeutics Inc; SVP, Elan Pharmaceuticals and various roles of increasing responsibility at SmithKline Beecham (GSK). In his varied career he has launched dozens of new medicines in several countries, completed tens of M&A transactions and managed many drug development programmes. Huw holds a PhD in neuropharmacology from the University of Birmingham, he is a passionate SCUBA diver and wine lover but never combines the two.”
MM - So would you like to take an educated guess?
I finally dipped a toe in, admittedly only 8k but it's a start.
A couple of cracking buys there...and as you say this has been going on for a while now. atb
1 x 300k and 1 x250k both at 12.30p....Looks like the share accumulation continues imho,...a disclosure on events could be close now the new CEO has been announced...this will go ballistic if a strategic investor is the reason behind the share transfers/ accumulation over several months...Gla :-
Many thanks for a lot of information from the regulars.
I might have missed a good opportunity to make a start @ 11.2p but had not done sufficient reading of the subject matter. Have some spare cash but making mistakes in the 70s are best avoided.
I agree the PR needs to be beefed up.
Evgen is all set for a significant re-rate or two as good news rolls in from this current bargain low....SFX-01 in evaluation for multiple disease targets with high profile academic researchers, with phase 2b trials for breast cancer in the planning as well as the phase 2/3 Covid-19 trials....the current lowly market cap does not reflect true and fair value of the current development status of SFX-01 , especially with similar stage Bio's valued at $100's of millions....and so hopefully the new CEO will be the catalyst for full appreciation and significant and substantial returns....BIG pharma could also be a pivotal factor in proceedings. Gl :-)
Prof Chalmers..lead investigator for SFX-01 Covid-19 patient trials. Gla :-)
James D Chalmers
@ProfJDChalmers
·
2h
Current R0 estimate in Scotland is 1.2 to 1.6 (approx. 3.7 in March/April). Anything above 1 means cases continue to rise. The best option is to get the number below 1 - that means sustainable control of the virus. A circuit break means a temporary drop to 0.5/0.6
1
2
4
Show this thread
James D Chalmers
@ProfJDChalmers
·
2h
Nice to talk to #bbcgms
@BBCScotlandNews
about the latest COVID19 figures in Scotland. The problem with a "circuit break" i.e temporary lockdown is that its an acknowledgement we can't control the virus. Likely therefore to mean more "circuit breakers" e.g over Christmas
Mega. EVG need to get some PR out, interviews ect to start promoting the company to maximise potential
Ps Radar......HeeeeeHaaaaa....:-))))
Wow.. Looks like we have struck gold and the market still doesn't know about this.
Yep, and SFX-01 's STAT3 properties already validated in the outstanding phase 2 breast cancer results that were life changing for some patients and now we have confirmation that STAT3 is the Key to immune system inflammation ...Massive potential and prospects for Evgen and SFX-01...Gla ;-)
Wow...huge discovery.
This is crucial validation of the pertinence of Evgen's studies ...
Will take time for the market to see that so in the meantime I will stock up and wait for the science to be acknowledged :-)
LInk
https://www.miragenews.com/key-to-immune-system-inflammation-discovered/
WOW!!!.....STAT3 - Key to immune system inflammation discovered.....it's almost like getting a RNS this morning....Exciting news for Evgen and SFX-01 regardless and must add significant interest from the industry for any drug that is active against STAT3 , let alone NRF2...Gla ;-)
15/6/20
Barry Clare, Executive Chairman of Evgen Pharma, said: "We move forward with the confidence that the value of SFX-01 as a potential drug that is active against the two key pathways of Nrf2 and STAT3 will become increasingly clear. These pathways are of significance in a range of diseases including cancer, autism and those where oxidative stress is a factor. We therefore believe that the fundamentals are in place to underpin sustainable share price growth and deliver the undoubted potential of SFX-01. On behalf of myself and the Board, I would like to thank our shareholders for their continued support and we look forward to updating the market with positive news in the coming year."
Health
October 1, 2020 1:49 pm AEST
Key to immune system inflammation discovered
Hudson Institute scientists have discovered the key to how cells turn on inflammation and fight infection, providing the knowledge to potentially reduce or stop destructive inflammation in future.
The finding comes as the world finds itself in the grip of the SARS-CoV-2 viral pandemic, where raging inflammation caused by the body’s overwhelming immune response in some individuals can lead to death and debilitating ongoing symptoms.
“Inflammation arising from our own immune system response is now recognised as an underlying component of almost every disease,” said A/Prof Ashley Mansell co-author of the study published in Nature Communication. “This includes heart, lung, brain and infectious diseases, cancer, diabetes and chronic kidney, liver and autoimmune diseases.
“If we could reduce dysfunctional or exaggerated inflammation, we would reduce the suffering associated with these severe inflammatory diseases.
“Understanding how cells turn on inflammation provides the building blocks to do this, by potentially targeting these pathways to restrain or stop inflammation attacking the body.”
A/Prof Mansell said the discovery was like “finding how turning a key in a car ignition tells the engine to start producing energy to turn the wheels”.
The study found that a protein called STAT3 plays a critical role in communicating signals from surface sensors on the cell (macrophages) , to the cell’s engine room- the mitochondria – that a foreign invader has been identified.
This reprograms the mitochondria to kick-start energy production and usage to generate inflammation, said co-author Dr Dan Gough. “When an immune cell detects an infection, like bacteria, it rapidly changes its metabolism from a resting to an inflammatory state,” Dr Gough said.
“This provides the energy and building blocks to produce chemicals called cytokines, which fight off the infection. This metabolic or energetic ‘switch’ occurs in the engine room of cells – the mitochondria,” he said.
Hudson Institute Director, Professor Elizabeth Hartland said the discovery was pivotal to understanding how certain immune cells adapt their metabolic activity to drive inflammation.
“There has long been a gap in our knowledge of how macrophages take a signal from the cell surface and translate it to the mitochondria. Now, thanks to the work of our inflammation scientists at Hudson Institute, we have an answer to that question,” said Hudson Institute Director, Professor Elizabeth Hartland.
“This missing link is pivotal because it gives us a deep understanding of the signalling events in our immune system’s first line of defence – the inflammatory process. This discovery has big implications for further research into treatments for a wide range of inflammatory diseases.”